Guangdong Hybribio Biotech Co Ltd - Asset Resilience Ratio
Guangdong Hybribio Biotech Co Ltd (300639) has an Asset Resilience Ratio of 4.32% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2025)
This chart shows how Guangdong Hybribio Biotech Co Ltd's Asset Resilience Ratio has changed over time. Check Guangdong Hybribio Biotech Co Ltd (300639) strategic investment index to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Guangdong Hybribio Biotech Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 300639 company net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥182.52 Million | 4.32% |
| Total Liquid Assets | CN¥182.52 Million | 4.32% |
Asset Resilience Insights
- Limited Liquidity: Guangdong Hybribio Biotech Co Ltd maintains only 4.32% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Guangdong Hybribio Biotech Co Ltd Industry Peers by Asset Resilience Ratio
Compare Guangdong Hybribio Biotech Co Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ICON Public Limited Company
F:IJF |
Diagnostics & Research | 0.00% |
|
Fleury S.A.
SA:FLRY3 |
Diagnostics & Research | 16.06% |
|
Guangzhou Kingmed Diagnostics Group Co Ltd
SHG:603882 |
Diagnostics & Research | 0.14% |
|
Diagnósticos da América S.A
SA:DASA3 |
Diagnostics & Research | 10.42% |
|
Cowealth Medical China Co.Ltd.
SHG:603122 |
Diagnostics & Research | 2.25% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Cytogen Inc
KQ:217330 |
Diagnostics & Research | 32.97% |
|
Sonic Healthcare Ltd
AU:SHL |
Diagnostics & Research | 0.13% |
Annual Asset Resilience Ratio for Guangdong Hybribio Biotech Co Ltd (2019–2025)
The table below shows the annual Asset Resilience Ratio data for Guangdong Hybribio Biotech Co Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 5.79% | CN¥240.15 Million ≈ $35.14 Million |
CN¥4.15 Billion ≈ $606.93 Million |
+0.38pp |
| 2024-12-31 | 5.41% | CN¥250.29 Million ≈ $36.62 Million |
CN¥4.62 Billion ≈ $676.49 Million |
+0.05pp |
| 2023-12-31 | 5.36% | CN¥307.05 Million ≈ $44.93 Million |
CN¥5.73 Billion ≈ $837.86 Million |
-0.39pp |
| 2022-12-31 | 5.75% | CN¥387.06 Million ≈ $56.64 Million |
CN¥6.73 Billion ≈ $984.98 Million |
-10.25pp |
| 2021-12-31 | 16.00% | CN¥677.14 Million ≈ $99.09 Million |
CN¥4.23 Billion ≈ $619.18 Million |
-14.10pp |
| 2020-12-31 | 30.10% | CN¥860.00 Million ≈ $125.85 Million |
CN¥2.86 Billion ≈ $418.06 Million |
+29.72pp |
| 2019-12-31 | 0.39% | CN¥5.00 Million ≈ $731.66K |
CN¥1.30 Billion ≈ $189.79 Million |
-- |
About Guangdong Hybribio Biotech Co Ltd
Guangdong Hybribio Biotech Co.,Ltd. engages in the research and development, manufacture, and sale of nucleic acid molecular diagnostic products for hospitals and medical institutes. It provides in-vitro diagnostic kits for human papilloma virus, sexually transmitted diseases (STD), thalassemia, and prenatal and postnatal. The company also offers STD real time PCR kits; hepatitis B virus real-tim… Read more